Comparative Pharmacology
Head-to-head clinical analysis: CELESTONE SOLUSPAN versus FLUOROMETHOLONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CELESTONE SOLUSPAN versus FLUOROMETHOLONE.
CELESTONE SOLUSPAN vs FLUOROMETHOLONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and decreasing immune cell activity.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce phospholipase A2 inhibitory proteins, thereby reducing prostaglandin and leukotriene synthesis. Exhibits anti-inflammatory, antipruritic, and vasoconstrictive effects.
1-2 mL (6-12 mg/mL betamethasone acetate and betamethasone sodium phosphate) intramuscularly or intralesionally, repeat every 1-4 weeks as needed.
1-2 drops of 0.1% suspension in conjunctival sac 2-4 times daily; severe cases: every 4 hours initially, then taper. Ointment: 0.5 inch ribbon 1-3 times daily.
None Documented
None Documented
Clinical Note
moderateFluorometholone + Gatifloxacin
"The risk or severity of adverse effects can be increased when Fluorometholone is combined with Gatifloxacin."
Clinical Note
moderateFluorometholone + Rosoxacin
"The risk or severity of adverse effects can be increased when Fluorometholone is combined with Rosoxacin."
Clinical Note
moderateFluorometholone + Levofloxacin
"The risk or severity of adverse effects can be increased when Fluorometholone is combined with Levofloxacin."
Clinical Note
moderatePlasma terminal half-life: betamethasone phosphate ~3-5 hours; betamethasone acetate ~6-8 hours. Clinical duration extended due to ester hydrolysis and depot effect (up to 7-14 days for IM injection).
Terminal elimination half-life: 1.3–2.2 hours; However, the pharmacodynamic half-life (duration of adrenal suppression) is longer (~24–36 hours) due to receptor-mediated effects.
Renal: ~65% as metabolites and unchanged drug; biliary/fecal: ~20%; remainder via other pathways.
Renal (primarily as metabolites): ~70%; Fecal: ~20%; Unchanged in urine: <5%
Category C
Category A/B
Corticosteroid
Corticosteroid
Fluorometholone + Trovafloxacin
"The risk or severity of adverse effects can be increased when Fluorometholone is combined with Trovafloxacin."